Dr Nicola Gullick (Consultant)

About Dr Nicola Gullick

• Role: Consultant
  
• Year of First Medical Qualification: 1999
  
• Location of Medical Training: Nottingham
  
• Date Joined University Hospitals Coventry & Warwickshire: 2017
  
• Membership of Professional / National / Regional Bodies:
  Fellow of the Royal College of Physicians of London
  British Society for Rheumatology
  Member of Psoriatic Arthritis and Drug Monitoring Guideline Working Groups
  British Psoriatic Arthritis Consortium (Brit-PACT) – Chair and Trustee
  
• Other Professional Details:
  BMedSci (Nottingham): 1997
  BMBS (Nottingham): 1999
  MRCP(UK): 2003
  MSc Rheumatology (King’s College London): 2006
  PhD Rheumatology (King’s College London): 2011
  FRCP: 2016
  Focused Ultrasound Course (Christ Church University, Canterbury): 2018
  
  Research profile
  I am a Consultant in Rheumatology and Honorary lecturer at the University of Warwick. I lead research within the rheumatology department. UHCW is part of the Arthritis Therapy Acceleration Programme in collaboration with the Universities of Birmingham and Oxford and I lead the Psoriatic Arthritis Theme. I am Principal Investigator for multiple investigator-led and commercial clinical trials in Psoriatic Arthritis, Rheumatoid Arthritis, lupus and polymyalgia rheumatica.
  
  Recent Publications:
  1.
  Raaphorst J, Gullick NJ, Pipitone N, Shokraneh F, Brassington R, Ali SSasha, Gordon PA. Immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies (Protocol). Cochrane Database of Systematic Reviews 2023, Issue 1. Art. No.: CD014510.
  2.
  Campanholo CB, Maharaj AB, Corp N, Bell S, Costa L, de Vlam K, Gullick NJ, et al. Management of Psoriatic Arthritis in Patients with comorbidities: an updated literature review informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol 2022 doi: 10.3899/jrheum.220310.
  3.
  Coates LC, Garrood T, Gullick N, Helliwell P, Kent T, Marks J, et al. Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. Rheumatology (Oxford) 2022 keac388. doi: 10.1093/rheumatology/keac388.
  4.
  Kiltz U, Sfikakis PP, Gaffney K, Sator PG, Bounas A, Gullick N, Espesailles E, et al. Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab Rheumatol Ther 2022 8:1-14. doi: 10.1007/s40744-022-00460-x.
  5.
  Abhishek A, Boyton RJ, Peckham N, McKnight Á, Coates LC, Bluett J, et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. (as VROOM Investigator) Lancet Respir Med 2022;10:840-50. Doi:10.1016/S2214-2600(22)00186-2.
  6.
  Tucker L, Allen A, Chandler D, Ciurtin C, Dick A, Foulkes A, Gullick N, et al. Executive Summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs Rheumatology (Oxford) 2022 keac260. doi: 10.1093/rheumatology/keac260.
  
• Special Interests:
  Psoriatic arthritis, Clinical Trials, Ultrasound, Research, Sarcoidosis
  

Contact Information

University Hospital Coventry
Clifford Bridge Road, Coventry CV2 2DX

Office: +44(0)2476 966705 (internal 26705)
Secretary Email: RheumatologySecretaries@uhcw.nhs.uk